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ABSTRACT
Mechanism of recuing Runx2 haplodeficiency-induced
cleidocranial dysplasia by histone deacetylase inhibition
Han-Sol Bae
Department of Molecular Genetics
The Graduate School
Seoul National University
(Directed by Prof. Hyun-Mo Ryoo, D.D.S., Ph.D.)
     Runx2 is a key transcriptional factor of early osteogenesis. Abnormally 
expressed Runx2 due to disturbance of transcription and post-translational 
regulation is closely associated to various bone disease. In this study, we focused 
on cleidocranial dysplasia (CCD) and studied efficacy of drugs in terms of 
molecular biology and epigenetics to recover the disease.
CCD is a genetic skeletal disorder primarily affecting the development of the 
bones which is caused by Runx2 haploinsufficiency. As it follows autosomal 
dominant inheritance pattern, even if one of the parents has a disease, it can be 
inherited to a child with a 50% probability. Most of CCD patients have symptoms 
that defective clavicles and large fontanellels due to delayed skeletal development. 
Generally, it is caused by Runx2 haploinsufficiency. Numerous studies have 
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investigated RUNX2 function in bone development and osteoporosis; to date, 
however, no therapeutic strategy has been proposed for CCD. Therefore, we try to 
discover a way to overcome the disease with therapeutic regimen. Previous report 
suggests that there is a critical threshold of Runx2 mRNA level for the development 
of CCD phenotypes. Based on these findings, we assumed that the phenotypes of 
CCD could be relieved when the functional Runx2 which have normal
transcription activity is induced up to a certain degree in the patient. 
In part I, we showed that in utero treatment of MS-275 which is kind of a 
class I histone deacetylase (HDAC) inhibitor, prevented delayed ossification of 
calvarial bones in Runx2+/- mice a model animal of CCD. Through several 
experimental analysis, we demonstrated that this effect was mediated via two 
different mechanisms: 1. post-translational acetylation of Runx2 protein, which 
proevented the protein from proteosomal degradation and then promoted its 
transacting activity; 2. increased expression of Runx2 and osteogenic bone marker 
genes through epigenetic regulation. In addition, we reveal that MS-275 promotes 
proliferation of osteoblast both in vitro and in vivo implying that delayed closure of 
cranial sutures in CCD is strongly associated with the reduced number of 
osteoprogenitor cells in frontal area as well as the delayed osteogenesis. In this 
study, we were able to identify the pathogenic mechanism of CCD and suggested 
the possibility of treating it with pharmacotherapy. 
Next, in part II, we carried out gene expression analysis by RNA-sequencing 
in primary mouse calvarial cells to validate the in vivo results from part I. Through 
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the Bioinformatics technique, we were able to examine the in vitro changes by 
Runx2 deficiency and MS-275 treatment at the genomic level. Thereby, we could 
make linkage between skeletal development and regulation of gene expression.
Collectively, we demonstrate here that MS-275 exerted its specific 
therapeutic effect by promoting proliferation, induction ability of osteoblast 
differentiation and regulating extracellular matrix of osteogenic front cells in the 
suture region. These results from this study provide the prospective advantages of 
the therapeutic approach using of MS-275 to alleviate symptoms of CCD and 
understanding of functional role of MS-275 on osteoprogenitor cells during 
osteogenesis.
Keyword : Cleidocranial dysplasia, Histone deacetylase inhibitor, MS-275, Runx2, 
Osteogenesis, Skeletogenesis
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Skeletogenesis is an important process in vertebrates to generate and 
maintain skeletal structure. The skeleton plays critical roles in supporting muscle, 
protecting vital organs, affording niche for cells in the immune system, and 
regulating metabolism as an endocrine and mechanical organ(1-3). During 
development and regeneration, bones go through two distinct processes; 
endochondral ossification and intramembranous ossification(4). In the process of 
endochondral ossification, firstly it requires to form a cartilaginous template by 
mesenchymal stem cells (MSCs) condensation which undergo differentiation into 
chondrocytes. Sequentially proliferated and matured chondrocytes form cartilage 
matrix, recruit osteoblast and allow vascularization. Mature osteoblast secretes
collagens and other bone-specific proteins to produce new organic matrix which 
finally mineralized when the physiological signals brought via the circulation. By 
contrast, intramembranous bone formation arises from directly differentiated 
osteoblast from condensation of MSCs and neural crest progenitor cells. 
Subsequently, the matured osteoblasts express extracellular matrix genes including 
type I collagen, Osteopontin (Opn; referred to as Spp1 in Mouse Genome 
Informatics) and Osteocalcin thereby synthesize bone matrix(5). 
As the great majority of the organic matrix is collagen, it provides tensile 
strength. During ossification progresses, hydroxyapatite accumulates in the organic 
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matrix and calcification occurs, which provides compressive strength. Thus, 
matured bones are excellent composite material with a combination of collagen and 
minerals that have physical rigidity and flexibility.
I.2. Runx2 in the process of osteoblast differentiation
Osteoblasts are terminally differentiated cells of mesenchymal stem cells 
which are specialized to forming bone. They synthesize condensed, cross-linked 
collagen and a number of functional proteins to constitute the organic matrix of 
bone. Therefore, for osteoblast maturation, it is necessary osteoprogenitors must 
express appropriate genes in a timely manner during differentiation progress. Gene 
expression is finely regulated by transcription factors such as Osterix and Runx2 
and the orchestrated activation of various physiological signals. Currently, 
epigenetic regulation has also been reported as a major regulatory mechanism of 
gene expression. 
Runt-related transcription factor 2 (Runx2/Cbfa1, AML3) is involved in 
osteoblast-specific member of the Runt transcription factor family. There are
consensus sequences specifically recognized by Runx2 as 5’-PyGPyGGT (Py/A)-
3’ or 5’-(Pu/T) ACCPuCPu-3’ (6). Runx2 is considered as a central transcription 
factor of osteogenesis as it has extensive spectrum of bone- and cartilage-related 
genes. In concert with physiological signaling pathways and other osteogenic 
transcription factors RUNX2 controls the functional activity of osteoblasts through
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regulate expression of bone marker genes including osteocalcin, alkaline 
phosphatase, type I and type X collagen in osteoblasts and chondrocytes (7,8).
Abnormal expression of Runx2 protein or Runx2 gene has been associated with 
developmentally compromised skeletogenesis and skeletal disease (9). Inactivated 
one allele of RUNX2 is characterized as the cause of human Cleidocranial dysplasia 
(CCD), by contrast, excessive expression of RUNX2 is a hall mark of 
craniosynostosys caused by constitutively active FGFR1 mutation (10,11).
Many osteogenic signaling pathways, such as BMP2, FGF2, TGF-β, and 
PTH, control transcription and functional activity of Runx2 during the early phases 
of osteogenesis (12). BMP2 signaling, for instance, upregulates the level of Runx2 
by stimulating Runx2 acetylation mediated by p300 and preventing Smurf1-
mediated degradation. The combination of signaling, TGF-β and BMP2, induces 
Runx2 expression and activated Smads (Smad1, -5, and -8) via physical interaction 
of BMP2 with Runx2 to drive osteoblast differentiation (13). In previous work (14-16), 
we demonstrated that the protein activity and stability of Runx2 are regulated by 
sequential post-translational modifications (PTMs) including phosphorylation, 
acetylation, prolyl isomerization, and ubiquitination. Among the PTMs of Runx2, 
acetylation of specific lysine residues in the COOH-terminal regoin is 
indispensable to stabilize and activate the function of protein (15,16). 
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I.3. Cleidocranial dysplasia
Cleidocranial dysplasia (CCD; MIM119600) is a bone-related genetic
disease that largely affects the development of the skeletal structures and teeth. 
This disease is caused by defect in the RUNX2 gene. Reduced or eliminated the 
activity of RUNX2 interferes with normal bone and cartilage development give rise 
to symptoms of CCD. The condition is either inherited from parents with an 
autosomal dominant manner or occurs by de novo mutation. As it is autosomal 
dominant disease, each child inherit the disease with a 50% chance even though 
only one of their parents is a patient. The individuals with CCD generally have 
abnormal tooth eruption, delayed development of cranial bones and clavicular 
hypoplasia. Furthermore, individuals with CCD are shorter than average height (17). 
Diagnosis of CCD can be made by a skeletal survey (series of X-ray 
analysis) for general adult or children. During pregnancy, a risk of fetus can be 
tested for CCD if the genetic cause of the condition has already been identified in a 
family member. This prenatal diagnosis can be carry out through DNA analysis of 
fetal cells isolated from amniocentesis or chorionic villus. CCD can also be 
diagnosis in a pregnancy by an ultrasound of fetus. The abnormal collarbones 
would be clearly observed after 14 weeks gestation. Nonetheless, there is nothing 
to do as a parent before, during, or after a pregnancy to cause CCD in a child. 
Because there is no specific medicine for bone deformities until now and 
management is based on each patient’s symptom.
The child who diagnosis around 5 year-old age, generally surgical 
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treatment is necessary to avoid any further worsening of the deformity. When bone 
density is lower than normal, the patient should take calcium and vitamin D and 
might start preventive treatment for osteoporosis at a young age. In case of the 
patient who has severe defects of the cranial vault such as symptoms of brain 
involvement in the place of skull should wear protective helmets during high-risk 
activities. If the mother has CCD, caesarian delivery should be performed. Some 
patient suffering from coxa vara should treated by surgery of corrective femoral 
osteotomies. If there is brachial plexus irritation with pain, excision of the 
clavicular fragments can be a therapeutic treatment to alleviate it (18-20).
I.4. Histone deacetylase (HDAC) and Histone deacetylase 
inhibitor (HDI)
DNA is condensed into form of chromatin with highly structured
nucleosome. Nucleosome is a basic structural subunit of chromatin which is 
comprised of an octamer of four core histone proteins, H2A, H2B, H3 and H4.
Histone octamer complex is composed of each pairs of core histones which are
coiled around 146 base pairs (bp) of DNA strand (21,22). Each single molecule of 
nucleosome is linked by 80 bp length of DNA strand called linker DNA. Through 
several reports, it is clearly identified that histone proteins are integral and dynamic 
component of the physical responsible for manipulating gene expression. DNA in 
resting cells is tightly compacted which prevents accessibility of RNA polymerase 
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II and transcription factors to their specific binding sites. The chromatin in this 
state is called as heterochromatin. During activation of gene transcription, on the 
other hand, the condensed chromatin is released, so called euchromatin and the 
recognition sequences are revealed to enable binding of the transcription factors. 
Histone protein modification is important in state conversion of chromatin; 
Heterochromatin to euchromatin. In general, hyper-acetylation of histone is linked 
with transcriptional activation, whereas histone hypo-acetylation is correlated with 
transcriptional inactivation (23). Attaching acetyl group to specific lysine residues in 
the N-terminal region of the core histone is assumed to neutralize the positive 
charge and to open chromatin structure for transcriptional factor bindings. The 
dynamic equilibrium of core histone acetylation of controlled by histone 
deacetylase (HDAC) and histone acetyl transferase (HAT) (22).
HDACs serves as an epigenetic regulator that regulate transcription by 
deacetylation of lysine residue of the histones. HDACs can also removing acetyl 
groups from non-histone proteins including Runx2, p53, and Stat3, render them 
more stable and/or increase localization to nuclear zone. In human and mouse, 
there are 18 kinds of HDACs which are categorized into four groups (class I, II, III, 
and IV) according to their function, structure, and subcellular localization. Class I, 
II and IV are enzymes which have zinc-dependent trait while enzymes involved in 
class III require NAD+ for enzymatic activity. Class I HDACs (HDAC 1-3, and 8)
show ubiquitous expression pattern in most tissue, and usually found in cellular 
nuclei. A number of studies have shown that enzymatic activity of class I HDAC is 
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necessary for gene transcription, as well as for DNA replication and repair, and cell 
survival and proliferation. Contrastively, class II HDACs (HDAC 4-7, 9, and 10) is 
reported to be expressed more tissue-specific, travel between cytoplasm and 
nucleus in response to physiological signaling stimulation. Some class II HDACs, 
HDAC6, for example, are demonstrated as affecting cytoskeletal and tubulin 
structure. However, most of HDACs in class II has considerably lower enzymatic 
activity compare with those of class I. The major function of class II HDACs are 
considered to recruit class I HDACs to regulatory region of target genes with their 
C-terminal deacetylase domain (24). The sirtuins (Sirts 1-7) belong to class IV 
HDAC which are involving regulation of genome stability, inflammation, energy 
metabolism, and aging. HDAC11 is the only member in Class IV that expressed 
across a variety of tissue, little has been investigated about its role. 
HDAC inhibitors (HDI) are collectively referred to as chemicals that are 
known to inhibit the enzymatic activity of HDAC. Commonly, HDIs belong to one 
of following six basic structural categories. (1) Short-chain fatty acids (Valproate, 
Sodium butyrate), (2) Cyclic peptides (FR01228, depsipeptide), (3) Benzamides 
(MS-275). (4) Hydroxamic acid (Suberoylanilide hydroxamic acid; SAHA, 
Trichostatin A), (5) Epoxyketones (Trapoxin), (6) Hybrid molecules (CHAP31, 
CHAP50). Several HDIs have approved from Food and Drug Administration 
(FDA) for clinical usage in United States. Among them, Valproate is the first HDI 
which approved for clinical use. It has been used as treatments for epilepsy and 
bipolar disorder. Romidepsin (Depsipeptide, Istodax) and SAHA (Vorinostat, 
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Zolinza) were approved for therapeutic use for cutaneous T-cell lymphoma. 
LBH589 (Panobinostat), MS-275 (Entinostat), ITI2357 (givinostat) are in various 
stages of clinical trials. The reasons that HDIs show therapeutic efficacy in a wide 
range of disease can be explained by effective correction of aberrant histone 
modification. Through HDI treatment, silenced genes such as tumor suppressors 
are expressed, the protein that has been inactivated is activated and the DNA repair 
mechanism is inhibit which can stimuli apoptosis. HDI-mediated chromatin 
relaxation may also make oncogenic cells more vulnerable to DNA damage from 
chemotherapies or radiation (24,25). The main reason that HDI is commonly used for 
cancer treatment is its ability to arrest the cell cycle by induction of p21. HDI 
perturb the formation of dimers from cyclins and cyclin-dependent kinase. Thereby 
it leads cell cycle arrest and induces cell differentiation (26).
Numerous studies now indicate that HDIs stimulate osteoblast 
differentiation both background of in vitro and in vivo. Westerndorf et al. reported 
that HDAC inhibitors increased production of alkaline phosphatase (Alp) and 
matrix mineralization of in vitro-cultured osteoblastic cells and ex vivo-cultured
calvaria (27,28). Some HDIs are demonstrated that increased the expression of Rankl
and Osteopontin in osteoblasts and accelerated osteoblast differentiation which is
derived from bone marrow mesenchymal stem cells (BMSCs) by promoting Erk 
signaling. In contrast to their positive regulatory effects on osteoblast
differentiation, HDIs decreased osteoclastogenesis by inhibiting the survival and 
maturation of osteoclasts. TSA inhibited osteoclasts differentiation from 
9
hematopoietic bone marrow cells and induced apoptosis through increasing p21WAF
expression. It has also been reported that SAHA disturbs osteoclastogenesis via 
activation of the NF-κB signaling. However, recent studies demonstrated that 
epileptic patients who have been prescribed VPA for a long-term tend to show 
symptoms of osteopenia/osteoporosis with increased fracture risk. The bone loss 
mechanism by VPA administration is not clear but deduced that it might be 
associated with certain characteristics of epilepsy including insufficient calcium 




All cell culture media and antibiotics were from Hyclone (GE Healthcare, Little 
Chalfont, UK). Cells used in this study were cultured at 37°C, in 5% CO2. Primary 
calvarial cells from wild type (WT) and Runx2+/- mouse were isolated from P0
mice calvarial bone and cultured in alpha MEM with 10% FBS containing 1% 
penicillin and streptomycin antibiotics. The osteogenic media for osteoblast 
differentiation, containing 50 µg/ml ascorbic acid and 5 mM β-glycerophosphate in 
alpha MEM.
2. Cytotoxicity test and cell proliferation assay
To test the cytotoxicity of MS-275, cells were seeded at a confluence of 2x103 cells 
in 96-well tissue culture plates, and treated with MS-275 for 48 hr. Water-soluble 
tetrazolium assay was performed for measurement of the number of viable and 
proliferated cells by using EZ-CyTox solution (Daeil Lab Service, Seoul, Korea). 
Experiments were conducted according to the manufacturer’s instruction. To 
examine the rate of induced proliferation, culture the cells in two of 96-well tissue 
culture dish and measure the cell number at day 1 and day 6 each with same 
process.
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3. Alkaline phosphatase (ALP) staining
Cells were cultured for 3 days to 5 days with or without chemical treatment. 
Sequentially, cells were washed with phosphate buffered saline (PBS) twice, fixed 
in solution of 2% paraformaldehyde, and then stained for alkaline phosphatase with 
staining solution according to the manufacturer’s instruction (Sigma, St. Louis, MO, 
USA)
4. Alizarin Red S (ARS) staining
After primary calvarial cells were cultured in osteogenic differentiation medium for 
2 weeks, matrix mineralization was confirmed by Alizarin red S staining which 
stains calcium deposition. At the end of culture period, the cells were fixed with 
70% ethanol for 1 hr, washed with PBS and stained with Alizarin red S solution
(Sigma, St.Louis, MO, USA). To quantitatively determine the mineral content of 
each sample, eluted the stain using 0.5 N HCl containing 5% sodium dodecyl 
sulfate (SDS), and measured the absorbance at 415 nm wavelength. 
5. Reverse transcription-polymerase chain reaction (RT-
PCR) and Real-time PCR
Cho et al. described detailed experimental protocol previously (29). Isolated and 
homogenized calvarial tissues from littermate of WT and Runx2+/- mice were 
prepared follow by RNA extraction. RNA samples were reverse-transcribed by 
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using the PrimeScript RT kit (Takara Bio, Shiga, Japan). Quantitative real-time 
PCR was conducted by using Takara SYBR premix Ex Taq (Takara, Shiga, Japan) 
on an Applied Biosystems 7500 Real Time PCR system (Foster city, CA). Primers 
were synthesized by Integrated DNA technology (IDT, Coralville, IA). All samples 
were run in duplicate, and the relative expression levels of mRNA were normalized 
to those of glyceraldehyde-3-phosphate dehydrogenase (Gapdh). The primer sets 
for real-time PCR in this study are listed in Table 3.
6. Western blot analysis and immunoprecipitation
Cellular proteins from primary calvarial cells were extracted in a lysis buffer which 
consisting of 150 mM NaCl, 50 mM HEPES (pH 7.5), 100 mM NaF, 1mM EDTA, 
0.25% sodium deoxycholate, 1 mM DTT, 0.25% CHAPS, 1% Nonidet P-40, and 
10% glycerol supplemented with protease and phosphatase inhibitors, including 
Na3VO4. For the purpose of measuring the acetylation level, the buffer should be
supplemented with 1 mM NaB as previously described (15). Antibodies used for this 
experiment are listed in Table 1.
7. Immunofluorescence
The process of antigen retrieval is required for immunofluorescent detection of
Runx2. The specimens for Runx2 detection were fixed in 4% formaldehyde and 
boiled for antigen retrieval in Tris/EDTA buffer (pH 9.2) presence of 5% urea for 
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10 min. The cells were then treated with the primary antibody which detect Runx2 
or only IgG as a negative control and stained with fluorescent-conjugated 
secondary antibody. Visualization was equipped with a Carl Zeiss LSM700 
confocal microscope, and analyzed with associated software program, ZEN2011
(Carl Zeiss, Oberkochen, Germany) (30).
8. Immunohistochemistry
For immunohistochemistry, newborn mice were fixed in 4% paraformaldehyde
solution for 24 hr and dehydrated, and then embedded in paraffin using standard 
procedures. Serial paraffin sections (5 µm thicknesses) were prepared, and analyses 
of immunohistochemical samples were conducted with the Dako Cytomation 
Envision System (Dako, Glostrup, Denmark). The tissue samples which completed 
staining procedure were visualized on a conventional microscope operated with a 
DP72 digital camera (Olympus, Tokyo, Japan).
9. Plasmid construction
The construction of rat osteocalcin (OC) –Luc promoter and 6XOSE2-Luc reporter 
plasmids has been described previously (15,31). Myc-tagged Runx2 expression vector 
was kindly provided by Prof. SC Bae in Chungbuk National University. 
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10. Luciferase assay
The transcriptional activity of Runx2 protein was measured with the constructions 
of the rat Osteocalcin promoter-Luc or 6xOSE2-Luc reporter plasmid vectors. 
Cells were transfected transiently with the indicated plasmids. Transfection were 
operated through electroporation technique. 24 hr after transfection, MS-275 or 
vehicle was treated on cells followed by the measurement of luciferase activity 
after an overnight incubation. For luciferase assay, cellular lysates were prepared
with passive lysis buffer (Promega, WC, USA). After treatment of substrate from 
Bright-GloTM Luciferase system (Promega, WC, USA), luciferase activity was 
detected with a GloMax-Multi Detection System machine (Promega, WC, USA).
11. Chromatin immunoprecipitation (ChIP) assay
ChIP assays in this study were performed with primary mouse calvarial cells that 
were grown with or without MS-275. Prior to harvest, cells were incubated for 10 
min at room temperature in incomplete medium which is containing 1% 
formaldehyde. Cells were washed and harvested in ice-cold PBS containing 
protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 mM leupeptin, 1 
mg/ml pepstatin A, 10 mg/ml TPCK, 4 mg/ml bestatin, 17 mg/ml calpain, 1 mg/ml 
E64, and 10 mM sodium butyrate). Cell pellets were resuspended in SDS lysis 
buffer (1% SDS, 50 mM Tris-Cl, pH 8.1, 10 mM EDTA, with protease inhibitors 
as written above) for 10 min on ice. Samples were sonicated to fragmentation of
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the DNA length to 0.1–0.6 kbp (median length 0.4 kbp). After centrifugation of 
each samples, the supernatant was diluted 10-fold in dilution buffer (0.01% SDS,
1.2 mM EDTA, 1.1% Triton X-100, 16.7 mM NaCl, 16.7 mM Tris-Cl with pH 
8.1,) supplemented with a protease inhibitor mixture. Next, DNA-coated protein 
A/G-agarose was prepared by incubating 500 μl of beads with dilution buffer 
containing sonicated DNA of 10 mg/ml salmon sperm at 4 °C with agitation for 1 
hr. Excess DNA was removed by centrifugation followed by four times
consecutive washes of the beads with dilution buffer. Immunoprecipitation was 
performed with the acetylated histone H4 or methylated histone H3 antibodies in a 
1:100 dilution. A non-specific antibody against the unassociated hemagglutinin 
epitope tag was used as a negative control. After antibody treatment, samples were 
digested with RNase A (10 mg/ml) at 37 °C for 1 h and proteinase K (20 mg/ml) at 
42 °C for 2 h to eliminate RNA and proteins, respectively. Next, the DNA was 
recovered by DNA extraction kit (Cosmogenetech, Seoul, Korea). An aliquot of 
each fraction of DNA was used for PCR.
12. Methyl-Specific PCR (MSP)
Genomic DNA from cells for experiment was prepared by cellular DNA extraction 
using the LaboPass tissue miniprep kit (Cosmo Genetech, Seoul, Korea). The 
bisulfite conversion was conducted with EpiTect Fast DNA Bisulfite kit (Qiagen). 
Methyl-specific PCR (MSP) was performed using the LugenTM Sensi 5xPCR 
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premix solution (Lugen Sci Co., Seoul, Korea). The primer sets used for this study 
are listed in Table 3. Primer design for MSP was performed based on the 
Methprimer software (Li and Dahiya, 2002). Targeting sites of each primer are 
illustrated in Figure 8. The PCR band intensity which generated by MSP was
measured with ImageJ software (National Institutes of Health, Bethesda, MD), and 
expressed as the percentage of methylation which is able to show the ratio of 
methylated DNA to unmethylated DNA in target region of gene. The software 
program named EMBOSS CpG Plot (http://www.ebi.ac.uk/emboss/cpgplot) was 
used to figure out the region of CpG islands within target gene. All experiments in 
this study were performed with primary mouse calvarial cells
13. In vitro methylation assay
Runx2 promoter vector was used for this assay. Methylated reporter vectors were 
prepared through incubating the vector with M.SssI enzyme which works as a CpG 
methyltransferase (New England BioLabs, Beverly, MA) with treatment of the S-
adenosylmethionine (SAM) for 8 hr, at 37 °C, which is following the 
manufacturer’s instructions. The levels of DNA methylation was identified after
measure the resistance toward digestive enzyme, HpyCH4IV (New England 
BioLabs, Beverly, MA) through agarose gel electrophoresis.
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14. Animal experiments
Experimental mice with Runx2-deficient genotype were generated as described 
previously (32) and kept under specific pathogen-free (SPF) conditions in animal 
laboratory of Seoul National University. WT and Runx2+/- mice were mated to 
obtain genotype-matched littermates which expected to have equal ratios of both 
genotypes. Pregnant mice at 14.5 d.p.c. were injected with 10 mg/kg MS-275 
(Calbiochem, Darmstadt, Germany) intraperitoneally. The dose of MS-275 to 
administrate is decided after toxicity test by checking weight change during 
pregnancy and number of littermates. Fetal or newborn mice were sacrificed for 
each experiment. All animal studies were reviewed and approved by the Special 
Committee on Animal Welfare, Seoul National University, Seoul, Republic of 
Korea.
15. Skeletal staining
For skeletal staining, E17.5 Embryos or P0 newborn mice were exenterated, skin 
was peeled follow by fat tissue was removed. After overnight fixation in ethanol
with 95% concentration, samples were stained in alcian blue solution (150 mg 
Alcian blue, 800 ml 98% ethanol, 200 ml acetic acid) for 24 hr. Next, 3 additional
hours in 95% ethanol, they were transferred to 2% KOH for 24 hr. Overnight 
staining in Alizarin red solution (50 mg/l Alizarin red in 2% KOH) was 
sequentially performed and then skeletons of samples were cleared in solution of 
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1% KOH with 20% glycerol and gradually increase the amount of glycerol for 2-3 
week and stored in 100% glycerol as a final step.
16. Micro CT analysis
After the MS-275 injection, embryonic mice or P0 postnatal mice were sacrificed 
and performed fixation with 4% paraformaldehyde solution for 24 hr. (depends on 
size of sample) at 4 °C. Micro-CT scanning was equipped with inspeXio SMX-
100CT and analysis was conducted with TRI/3D-BON which is associated 
software program of inspeXio SMX-100CT (Shimadzu, Kyoto, Japan). After 
taking 3-dimenational images of micro-CT, samples were sequentially used for 
immuno-histochemistry or skeletal staining. 
17. Calvarial organ culture
E17.5 mice calvaria were dissected and covered skin was removed follow by
cultured in a Trowell-typed organ culture-specific dish. Calvarial explants were 
placed on Nucleopore filters with 0.1-mm pore size and cultured for 48 hr in 
osteogenic differentiation media presence or absence of 1μM MS-275 in a 
humidified and sterilized cell incubator with 5% CO2 in air at 37℃. The culture 
medium was freshly changed every two days. After 48 hr. organ culture progress, 
harvested explants were fixed in 4% paraformaldehyde (PFA) and performed serial 
dehydration with a graded concentration of ethanol. After dehydration, explants 
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were embedded in paraffin wax follow by sectioned to a 5 μm thickness.
18. Double Fluorescence labeling
Double fluorescence labeling assay was operated to determine new bone growth in 
organ culture system. The Pregnant mice were got intraperitoneal injection with 
primary labeling reagent, calcein (1 mg/ml, Sigma , St. Louis, MO, USA) in 2% 
sodium bicarbonate solution 1 day before sacrifice, following by calvarial tissue 
were isolated from each embryo for organ culture. During organ culture, 0.09 
mg/ml of alizarin complexone (Sigma , St. Louis, MO, USA) was supplied to the 
culture medium for secondary labeling. Double labeling samples with calcein-
labeled tissue (green-colored fluorescence) which indicates embryonic 
mineralization and alizarin complexone-labeled tissue (red-colored fluorescence) 
which represents mineralization were obtained from this technique. After tissue 
processing procedures, the labeled fluorescence was visualized on the confocal 
microscope.
19. Statistical analysis
All quantitative data are presented as means ± SD. Each experiment was performed 
at least three times, and results from individual representative experiments are 
shown in figures. Statistical differences were analyzed by Student’s t-test. p ≤ 0.05 
was considered to indicate a significant difference.
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20. RNA-seq. procedure and data analysis
In part I, calvaria of E17.5 mice which treated fetal administration of MS-275 or 
vehicle at E14.5 and E16.5 were eviscerated in biological triplicate and total RNA 
was extracted using the Qiazol reagent (Qiagen, Hilden, Germany). In part II, 
primary calvarial cells were isolated from postnatal day 2 (P2) mice. Isolated 
primary cells were cultured in presence or absence of 1μM MS-275 for 24hr and 
treated additional MS-275 or vehicle with osteogenic media at day 3 for 24 hr. 
Same protocol with part I for RNA isolation was performed. The mRNA in total 
RNA was converted into a library of template molecules which is appropriate for 
cluster generation using the Illumina TruSeq RNA Sample Preparation Kit. The 
TruSeq RNA libraries were quantitated by qPCR. Using these RNA libraries, 
paired-end sequencing with 76 bp read length was performed on the NextSeq500 
platform (Illumina, San Diego, CA, USA) to generate FASTQ-formatted sequence 
data. Transcriptome levels were determined from the RNA-seq reads via the 
following RNA-seq pipeline. First, to cut-off sequencing artifacts and poor quality 
bases, raw data quality control was conducted using Trimmomatic (v0.33) (33) with 
the following options: PE -phred33 ILLUMINACLIP:TruSeq3-PE.fa:2:30:10 
MINLEN:50 Trailing:20. Reads were mapped to the mouse genome reference 
(MM10) from the Ensembl database using Tophat2 (v2.1.0) (34). Conversion and 
sorting of the alignment file was performed using Samtools (v 0.1.19) (35). The 
HTseq package (36) was used to estimate the count of uniquely mapped reads for 
each of the 39,179 annotated genes in the gene transfer format (.GTF) file. From 
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this RNA-seq analysis pipeline, we obtained the expression level of 39,179 genes 
from 12 samples. The edgeR tool was used to detect differentially expressed genes 
(DEGs), which were classified as either up- or down-regulated depending on fold 
change. The DAVID Bioinformatics Resource 6.7 (NIAID, NIH) was used for 
Gene Ontology (GO) pathway analyses.
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Table 1. Antibodies used in this study.
Antigen Clone Cat.# Host Application Source










Histone H3 - Ab1791 Rb, pAb
WB, IP, IHC, 
IF, ChIP
MBL
β-actin C-4 Sc-47778 M, mAb
WB, IHC, IP, 
IHC, IF
Santa Cruz
Acetyl-H4 17-630 Rb, pAb WB, ChIP Millipore
Methyl-
H3K9
17-680 M, mAb WB, ChIP Millipore
MeCP Ab2828 Rb, pAb
WB, IP, IHC, 
ChIP
Abcam
M, mouse; Rb, rabbit; G, goat
mAb, monoclonal antibody; pAb, polyclonal antibody
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Table 2. Chemical reagents used in this study.
Chemical reagents Application Source
DMSO Pin1 inhibitor Calbiochem
MS-275 HDAC1,3 inhibitor Calbiochem
CHX Protein synthesis inhibitor Sigma-Aldrich
Calcein
Green fluorescence labeling 
reagent
Sigma-Aldrich
Alizarin complexone Red fluorescence labeling reagent Sigma-Aldrich
DMSO, Dimethylsulfoxide; VPA,Valproic acid; SAHA, suberoylanilide 
hydroxamic acid; CHX, Cycloheximide
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Table 3. Primer list used in this study.
For Real-time PCR
Name Oligonucleotide Sequence
Alp(forward) 5'- CCA ACT CTT TTG TGC CAG AGA-3'
Alp(reverse) 5'- GGC TAC ATT GGT GTT GAG CTT TT -3'
Osteocalcin (forward) 5'- CTG ACA AAG CCT TCA TGT CCA A -3'
Osteocalcin (reverse) 5'- GCG CCG GAG TCT GTT CAC TA  -3'
Collagen1α1(forward) 5'- GCTCCTCTTAGGGGCCACT - 3'
Collagen1α1 (reverse) 5'- CCACGTCTCACCATTGGGG -3'
Runx2 (forward) 5’-TTC TCC AAC CCA CGA ATG CAC -3’




ß-catenin (reverse) 5’-CTTGCCACTCAGGGAAGGA -3’
Pcna(forward) 5’-TTTGAGGCACGCCTGATCC -3’
Pcna(reverse) 5’-GGAGACGTGAGACGAGTCCAT -3’
Cyclin D1(forward) 5’-CCA AAA TGC CAG AGG CGG ATG AG -3’







Runx2, Methylated (Forward) 5’-AAGTTTGTAAAAATTTGTTTTTCGT-3’
Runx2, Methylated (Reverse) 5’-CTCAAACTACTCCGACTAACGTT-3’
Runx2 Unmethylated (Forward) 5'-AAGTTTGTAAAAATTTGTTTTTTGT-3’
Runx2 Unmethylated (Reverse) 5’-ACCTCAAACTACTCCAACTAACATT-3’
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The number of mice Total
WT
Veh. 31 12 23 23 17 9 115
MS. 35 7 9 19 10 16 96
Runx2+/-
Veh. 51 8 23 14 21 14 131
MS. 24 3 11 17 15 7 77
                       Total number of mice 419
Veh.; Vehicle. MS.; MS-275
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An HDAC inhibitor, Entinostat/MS-275, prevents delayed 
cranial suture closure in heterozygous Runx2 null mice
Abstract
Cleidocranial dysplasia (CCD) is an autosomal dominant skeletal disorder caused 
by mutations in RUNX2, coding a key transcription factor of early osteogenesis. 
CCD patients suffer from the developmental defects in cranial bones. Despite 
numerous investigations and clinical approaches, no therapeutic strategy has been 
suggested to prevent CCD. Here, we show that fetal administration of
Entinostat/MS-275, a class I histone deacetylase (HDAC)-specific inhibitor, 
partially prevents delayed closure of cranial sutures in Runx2+/- mice strain of 
C57BL/6J by two mechanisms: (1) post-translational acetylation of Runx2 protein, 
which stabilized the protein and activated its transcriptional activity; and (2) 
epigenetic regulation of Runx2 and other bone marker genes. Moreover, we show 
that MS-275 stimulates osteoblast proliferation effectively both in vivo and in vitro
suggesting that delayed skeletal development in CCD is closely related to the 
decreased number of progenitor cells as well as the delayed osteogenic 
differentiation. These findings provide the potential benefits of the therapeutic 
strategy using MS-275 to prevent CCD.
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Introduction
RUNX2, the central transcriptional factor of osteogenesis, regulates 
osteogenic cell proliferation and differentiation (32,37). In concert with other 
osteogenic transcription factors, including Osx, Dlx5, and NFI-C, RUNX2 controls 
the functions of osteoblasts to regulate expression of bone marker genes such as 
osteocalcin (7,8). Mouse fetuses harboring targeted disruption of Runx2 exhibit a 
complete lack of ossification due to maturation arrest of osteoblasts, indicating that 
this gene plays an indispensable role at the early stages of osteoblast differentiation 
(32,38). The biological and clinical significance of RUNX2 was established by the 
identification of a mutation in the RUNX2 gene locus in humans with cleidocranial 
dysplasia (CCD), an autosomal dominant skeletal disease (10,11). The symptoms of 
CCD include clavicular hypoplasia, delayed development, and ossification of 
cranial bones. Runx2+/- mice exhibit symptoms similar to those of human CCD 
patients (10,11), indicating the importance of RUNX2 in intramembranous bone 
formation. 
Previously, Lou et al. (39) established a mouse model in which Runx2
expression can be finely regulated by neo cassette. They found that the Runx2
mRNA level must drop below a critical threshold for CCD-like phenotypes to 
develop; mice expressing lower levels of Runx2 mRNA [55–70% of that in the 
wild type (WT)] developed CCD-like phenotypes, whereas mice with higher Runx2
mRNA levels (>79% of WT) developed a normal skeleton. These findings 
prompted us to hypothesize that symptoms of CCD could be alleviated when 
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functional Runx2 transcriptional activity is restored to the threshold level.
Many osteogenic signals, such as BMP2, TGF-β, FGF2, and PTH, 
regulate Runx2 expression during the early stages of osteogenesis (12). However, 
because of their non-specific effects on overall biological processes, it would be 
challenging to use these growth factors for human treatment. In previous works (14-
16), we showed that the stability and transactivation activity of Runx2 protein are 
regulated by serial post-translational modifications such as phosphorylation, prolyl 
isomerization, acetylation, and ubiquitination. Accordingly, modulation of one or 
more of these post-translational modifications of Runx2 represents a therapeutic 
target for treatment of the genetic disease CCD. 
Among the post-translational modifications of Runx2, acetylation of 
several lysine residues in Runx2 C-terminus is necessary to stabilize and activate 
the protein (15,16). Numerous in vitro studies illustrated that HDAC inhibitors (HDIs) 
induces acetylation of both histone and non-histone proteins, including Runx2 (14). 
In addition, our previous studies showed that MS-275, an HDI, exerts a strong bone 
anabolic effect in models of calvarial defect or osteoporosis in adult animals (27,40).
MS-275 is also known by the clinically as Entinostat (Syndax pharmaceuticals Inc.
USA) and currently being used in clinical trials for treating cancers. Based on these 
previous results, we hypothesize MS-275 also exerts a Runx2-mediated anabolic 
effect in the early stage of bone development in fetal animals. In this paper, we 
tested our hypothesis by administering MS-275 to Runx2-haplodeficient mice, a 




MS-275 restored CCD phenotypes in Runx2+/- mice 
To determine whether MS-275 can functionally compensate for CCD-like 
phenotypes in Runx2-deficient phenotypes, we established a single-injection 
regimen in which MS-275 was administered to pregnant mice. According to 
previous studies, dynamic skeletogenesis in cranial bones occurs between E14.5 
and birth (32,38). Therefore, we administered MS-275 at 14.5 d.p.c. and sacrificed 
fetuses at 16.5 d.p.c. All fetuses were evaluated for their level of bone 
developmental using measurements of ossified vertebrae length, ratio of ossified 
area over whole skull area, and sizes of the mandible and clavicle (Fig. 1A-H). 
MS-275 treatment had an effect on overall skeletal growth. Ossified vertebral 
length was 40% shorter in Runx2+/- than in their WT littermates, but MS-275 
treatment of Runx2+/- mice significantly increased their ossified vertebral lengths 
nearly to WT levels (Fig. 1A, B, p<0.05). Similar growth was observed in 
membranous bones including calvaria, mandibles, and clavicles. MS-275 treatment 
of Runx2+/- mice significantly (p<0.05) increased mineralization of these bones 
nearly to WT levels (Fig. 1C-H). In calvarial bone and mandible, the therapeutic 
effect of MS-275 was remarkable: Runx2+/- traits were recovered almost to the WT 
level. By contrast, the drug had a relatively small effect on clavicle development, 
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although the increase in mineralization was still significant (p<0.05) and the 
associated morphological change was meaningful. MS-275–treated clavicles 
exhibited a more developed skeletal curve, and development of their medial part 
(i.e., the region attached to sternal bone) was much more prominent than that of the 
lateral part (i.e., the region arranged with acromial bone) (Fig. 2). Importantly, the 
medial part of the clavicle arises via intramembranous bone formation, whereas the 
lateral part is formed by endochondral ossification (41). These results corresponded 
well with a previous report showing that Runx2 is more important for 
intramembranous than endochondral bone formation (32). Therefore, the rescue of 
CCD phenotypes by MS-275 treatment is more prominent in intramembranous 
bone development, as observed in this study. 
To determine whether MS-275 treatment affects bone development until 
they are born, we examined calvarial phenotypes of pups at P0 after single 
administration of MS-275 to pregnant mice at 14.5 d.p.c. Results of skeletal 
staining and microCT analysis revealed no significant difference between the MS-
275 and vehicle-treated groups (Fig. 3). However, because the half-life of MS-275 
is only 1 hr in rodents (42), a single injection may not be pharmacokinetically 
sufficient to cause medical effects that persist until birth. Therefore, we treated MS-
275 twice (14.5 and 16.5 d.p.c.) to minimize toxicity and maternal stress, and 
confirmed that double injection was effective. Under these treatment conditions, 
the CCD phenotypes of P0 Runx2+/- mice were almost comparably abolished, and 
the mice were nearly WT in appearance (Fig. 4A-C). In Fig. 4A, we observed that 
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MS-275 leads bone formation also in WT group. It is compatible with our previous 
research, which showed therapeutic value of MS-275 in osteoporosis-induced adult 
mice (40). Based on these data, it is clear that maintenance of an adequate 
therapeutic level of MS-275 is critical, and that a well-controlled pharmacokinetic 
study of its effects should be performed. 
To rule out maternal effects of MS-275, we employed a mouse calvarial 
organ culture system.  In Fig. 4D, calcein labeling of calcified tissue in utero was 
observed as green fluorescence, and newly mineralized tissue formed during organ 
culture was observed as red fluorescence. From these observations, we could 
estimate growth through the effect of MS-275 treatment alone. MS-275 treatment 
caused a strong increase in newly generated calvarial bone in both genotypes of 
mice, but the recovery effect was more dramatic in Runx2+/- than in WT mice (Fig. 
4D). Thus, the distance between osteogenic fronts of parietal bones was closer in 
the presence of MS-275. The results of coronal sectional view strongly supports 
this observation (Fig. 1D, E). It is notable that MS-275 stimulates mineralization 
on the osteogenic front. Therefore, these results indicated that MS-275 is a positive 
regulator of intramembranous bone formation in vivo.
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Fig. 1. MS-275 rescues the CCD-like phenotypes in Runx2+/- mice. Fetuses were
treated with MS-275 or vehicle either once at 14.5 d.p.c. or twice at 14.5 and 16.5
d.p.c. in utero. (A) Representative skeletal staining of E16.5 WT and Runx2+/- mice 
that received one injection in utero. (Scale bar, 5 mm) (B) Lengths of ossified 
spinal bone. The same samples were cut into (C) calvaria (Scale bar, 2 mm) and 
(D) mandible (Scale bar, 2 mm) (E) clavicles (Scale bar, 1 mm) (F–H) Quantitative 
analysis of each sample is depicted as scatter plot graphs to the right of each figure. 
Developing clavicles exhibit a significant increase in mineralized area. Quantitative 
data were obtained using the ImageJ software. Veh.= Vehicle, MS.= MS-275. 
*P<0.05, **P<0.01, ***P<0.001, Student’s t-test.
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Fig. 2. MS-275 induced intramembranous development of clavicles in both 
WT and Runx2+/- fetal mice. (A) Magnified images of Fig. 1E. Dotted lines 
indicate development of intramembranously formed bone from concave curves. 
MS-275–treated clavicles exhibited a more developed skeletal curve, and 
development of their medial part (i.e., the region attached to sternal bone) was 
much more prominent than that of the lateral part (i.e., the region arranged with 
acromial bone). Importantly, the medial part of the clavicle arises via 
intramembranous bone formation, whereas the lateral part is formed by 
endochondral ossification. These results indicated that the rescue of CCD 
phenotypes by MS-275 treatment is more prominent in intramembranous bone 
development. (Scale bar, 200 µm) (B) Skeletal staining images were acquired with 
all bones in their original positions to determine the morphological directions of the 
clavicles. (Scale bar, 1 mm). Ac: acromial end; St: sternal end; Endo: endochondral 
ossification; Intra; intramembranous ossification.
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Fig. 3. A single administration of MS-275 had no significant effect on P0 
skeletons. (A) Representative skeletal staining images of newborn mice. Mice 
were treated with vehicle or 10 mg/kg MS-275 once at E14.5. Long bone 
development was not significantly perturbed by Runx2 deficiency at the postnatal 
stage. (Scale bar, 5 mm) (B) Ossified spinal bone lengths. (C) Dissected calvaria 
from (A) (Scale bar, 5 mm). (D) Ossification level of each sample. (E) 
Representative microCTs of skulls from newborn WT and Runx2+/- mice that 
received the indicated chemicals at E14.5 (scale bar, 5 mm). Ossification level of 
each group was measured as (F) % of ossified area over full skull and (G) distance 
between parietal bones. Quantitative data were obtained using ImageJ. Data 
represent means ± SD (n=15 to 20). Data followed a normal distribution. Veh.: 
vehicle; MS.: MS-275; *P<0.05, **P<0.01, ***P<0.001, Student’s t-test.
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Fig. 4. Multiple administrations of MS-275 show significant effect on Runx2+/-
mice. (A) Representative microCTs of skulls from newborn WT and Runx2+/- mice 
that received the indicated chemicals at E14.5 and E16.5. The asterisk (*) indicates 
rescue of CCD-like phenotype on calvaria. Ossification level of each group was 
measured as (B) % of ossified area over full skull area and (C) width between 
parietal bones. (D) Double fluorescence reveals new bone growth in organ-cultured 
E17.5 calvarial tissue. The tissue was visualized by fluorescence microscopy as 
whole tissue (upper) or coronal sections (lower). (Scale bar, 1 mm) (E) Suture 
width of (D) was measured. Quantitative data were obtained using the ImageJ 
software. Veh.= Vehicle, MS.= MS-275. *P<0.05, **P<0.01, ***P<0.001, 
Student’s t-test.
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MS-275 restores Runx2 protein acetylation and stabilizes its 
transactivating activity in Runx2+/- calvaria cells.
We showed previously that HDIs stabilizes Runx2 by post-translational 
modification (15); however, it remains unclear whether it could compensate for 
Runx2 activity in Runx2-deficient organisms. To address this possibility, we 
examined the changes of acetylated Runx2 level in WT and Runx2+/- calvarial cells 
following MS-275 treatment. Immunoprecipitation and immunoblot analysis 
showed that acetylation of Runx2 was lower in Runx2+/- mouse calvarial cells than 
in WT cells. By contrast, acetylated Runx2 level of MS-275 treated Runx2+/- mouse 
calvaria cells was restored to that of the WT-vehicle treated group (Fig. 5A). To 
determine whether MS-275 increases the amount of Runx2 protein, we examined 
the endogenous Runx2 level. Indeed, the amount of Runx2 increased in a dose-
dependent manner upon MS-275 treatment (Fig. 5B, C). 
Next, we investigated whether MS-275 stabilizes the Runx2 protein. The 
degradation rate was lower in the MS-275–treated group than in the vehicle-treated 
group: specifically, the half-life of Runx2 was 13.02 hr in the absence of MS-275 
and 18.15 hr in the presence of MS-275 (Fig. 5D, E). Moreover, 
immunofluorescence assays revealed that the total Runx2 protein level was 
elevated in both genotypes of MS-275–treated mouse calvarial cells. In the 
Runx2+/- cells, the expression level of Runx2 protein in nucleus was restored to WT 
levels (Fig. 5F, G). We observed similar Runx2 expression patterns in mouse 
calvarial tissue. The amount of Runx2 protein accumulated in the nucleus of 
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osteoblasts around calvarial bone was elevated in MS-275 treated Runx2+/- mouse 
calvaria (Fig. 6). Because both acetylation and ubiquitination occur at similar 
lysine residues (43), this observation could be attributed to a protective mechanism 
that inhibits the ubiquitination and proteosomal degradation pathway.  
To determine whether MS-275 affects Runx2 transactivating activity, we 
carried out reporter assays. The results show that MS-275 up-regulated Runx2 
transcription activity in mouse calvarial cells of both genotypes. Remarkably, a 
high dose of MS-275 restored Runx2 transactivating activity in Runx2+/- cells to 
WT levels (Fig. 7A). Additionally, because Osteocalcin is a direct target of Runx2 
(44), we investigated the role of MS-275 on Runx2-mediated promoter activity. 
Runx2 overexpression significantly activated Osteocalcin promoter activity, but 
not the activity of a mutant reporter gene with an altered Runx2-binding site. 
Runx2 overexpression and MS-275 treatment synergistically stimulated osteocalcin 
promoter activity. On the other hand, Runx2 overexpression could not stimulate the 
mutant OC-promoter with the altered Runx2 binding-site mutant, whereas MS-275 
could still stimulate the mutant construct (Fig.7B).  Based on these observations, 
we hypothesize that MS-275 might influence on not only Runx2, but also other 
transcription factors that bind in that region. These results suggest that MS-275 
enhances transcription activity of Runx2 via post-translational acetylation of 
Runx2. 
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Fig. 5. MS-275 stabilizes Runx2 protein. (A) WT and Runx2+/- mouse calvaria 
cells were cultured in the presence or absence of 1 µM MS-275 for 24 hr. 
Acetylated Runx2 was measured by immunoprecipitation (IP). Since amount of 
Runx2 in Runx2+/- is almost half of that in WT, equal amounts of Runx2 Inputs 
were estimated and normalized before IP. (B) Primary osteoblasts were cultured 
with MS-275 for 24 hr, and the abundance of endogenous Runx2 protein was 
examined by IB. (C) Protein band intensities in (B). (D) Following transfection 
with Myc-tagged Runx2 primary calvaria cells were treated with or without 1 µM 
MS-275 for 24hr and cultured with cycloheximide (CHX, 10 µg/ml) for the 
indicated times. Levels of Runx2 were assessed by detecting Myc protein. (E) 
Estimated change of Runx2 expression level over time. (F) Runx2 in each 
genotype of calvarial cells was detected after treatment with 1 µM MS-275 for 24 
hr. (Scale bar, 10 µm). (G) Number of nuclear Runx2 foci in (F). Quantitative data 
were obtained using ImageJ. Veh.= Vehicle, MS.= MS-275, E.V.= Empty vector, 
*P<0.05, **P<0.01, ***P<0.001, Student’s t-test.
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Fig. 6. MS-275 increases amount of Runx2 protein in mouse calvarial tissue.
Runx2 levels in P0 mice calvarial tissue were determined by 
immunohistochemistry. Arrows indicate Runx2-positive osteoblasts. Enlargement 
of the boxed regions are displayed on the right side. 
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Fig. 7. MS-275 activates Runx2 transacting activity. (A) Runx2-transactivating 
activity following 24 hr treatment of calvarial cells with the indicated dose of MS-
275, assessed by luciferase assay using the 6XOSE2 reporter gene. The red line 
indicates the activity of vehicle-treated WT. (B) HEK293T cells were transfected 
with WT (-208 OC-Luc) or Runx2-binding site mutant osteocalcin (OC) promoter–
Luc (-208 RUNX-mut) with or without Runx2 overexpression. Luciferase activity 
was measured following treatment with 3 µM MS-275 or vehicle for 24 hr. Veh.= 
Vehicle, MS.= MS-275, E.V.= Empty vector. *P<0.05, **P<0.01, ***P<0.001, 
#P<0.0001, Student’s t-test.
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MS-275 induces epigenetic regulation of the Runx2 promoter region 
Previous studies showed that MS-275 works as a chromatin modulator 
(epidrug) on stem cells and affects their potency and differentiation (45). These 
observations led us to hypothesize that treatment of MS-275 would change the 
epigenetic landscape of primary calvarial cells. Runx2 has at least two different 
isoforms using alternative promoters, which show differential expression patterns 
in mouse calvaria development (46). P1 promoter (Distal) drives transcription of 
type-II Runx2 (Runx2-II) known for bone-specific-expression whereas P2 promoter 
(Proximal) induces Type-I Runx2 (Runx2-I) expression in undifferentiated 
mesenchymal stem cell, preosteoblasts and chondrocyte precursors. In silico
analysis predicted the existence of CpG islands in the Runx2-P2 promoter region 
that are conserved among species (47). These CpG islands are located near the 
transcription start site. Using that region as an epigenetic target, we measured 
Runx2 expression and observed changes in several epigenetic markers(47) (Fig. 8).
First, we confirmed that Runx2 expression levels in primary mouse 
calvarial cells were increased by MS-275 treatment (Fig. 9A). To investigate 
whether MS-275 has an epigenetic function, we performed chromatin 
immunoprecipitation (ChIP) assays (Fig. 9B). We checked the levels of acetylated 
histone H4 (Ac-H4), di-methylated histone H3K9 (Me-H3K9) and methyl CpG 
binding protein 2 (MeCP2) (48). The level of acetylated histone H4 (Ac-H4), a 
hallmark of transcriptionally activated genes (49), was increased by MS-275 
treatment. By contrast, the levels of methylated H3K9 (Me-H3K9) and methyl 
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CpG binding protein 2 (MeCP2) binding, both of which are markers of epigenetic 
suppression (50), decreased following MS-275 treatment (Fig. 9B). Methylated 
histones control skeletal development, and down-regulation of histone methylation 
in osteoblasts increases bone formation (51,52). The results of the ChIP assay 
revealed genomic interactions of epigenetic factors with the Runx2 promoter 
region; these interactions finely reflect the trend of Runx2 expression as shown in 
Fig. 9A. Thus, we were able to deduce MS-275 activates Runx2 promoter.  
Next, we carried out methylation-specific PCR to measure the DNA 
methylation status of the Runx2 promoter. Usually, hypermethylated DNA 
indicates a transcriptionally inactivated state (53). We found that MS-275 treatment 
decreased the amount of methylated PCR products and increased the amount of 
unmethylated-DNA fragments in primary calvarial cells. Thus, MS-275 causes 
hypomethylation of 5’-cytosine in CpG islands of the Runx2-I promoter (Fig. 9C). 
Runx2 gene expression (Fig. 9A) was inversely correlated with the methylation 
level of the CpG island in Runx2 promoter (Fig. 9C). This result also suggested that 
Runx2 was transcriptionally activated by MS-275. To confirm the ability of MS-
275 to activate the Runx2 gene, we performed an artificial in vitro methylation 
assay using M.SssI methyltransferase, as previously described (54). The HpyCH4IV
restriction enzyme was used to validate promoter construct methylation: this 
enzyme recognizes the sequence ACGT and cuts selectively at sites containing 
unmethylated cytosine, but cannot cut at CpG sites methylated by M.SssI (Fig. 9D). 
To assess the functional effects of MS-275 on CpG-methylated gene expression, 
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we analyzed Runx2 promoter activity in luciferase reporter assays using in vitro
methylated or unmethylated constructs. We found that a construct inactivated by 
CpG methylation was activated by MS-275 in a dose-dependent manner (Fig. 9E). 
These results also correspond with patterns of Runx2 expression (Fig. 9A) and CpG 
methylation (Fig. 9C). In aspects of histone modification, our results of ChIP assay 
and immune blot assay were also comparable with previous study, which 
demonstrated marked histone modification dynamics during osteoblast 
differentiation (Fig. 9B, Fig. 10). In the process of osteogenesis, promoter region of
Runx2 experienced elevated H3 and H4 acetylation and reduced H3K9, H3K27 
methylation whereas global level of those hall marks were not changed (48). 
Altogether, our in vitro results suggest that MS-275 induced Runx2 expression by 
affecting the epigenetic landscape of the Runx2 promoter region, which might 
increase the potential of primary calvarial cells to develop into mature osteoblasts.
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Fig. 8. The structure of Runx2 genome and derived transcripts. The Runx2 
gene consist of eight exons and two alternative promoters; P1 and P2 promoter. P1 
is a distal promoter which regulates the transcription of type-II Runx2 coding type-
II Runx2 protein starting at MRIPV amino terminus. P2 is a proximal promoter 
involved in type-I Runx2 expression coding type-I Runx2 protein containing 
MASNS amino terminus. CpG island is located at the region of P2 promoter. The 
diagram is showing the overall targeting sites of primers study for RT-PCR, 
Methyl-Specific PCR, and ChIP-qPCR. Sequence of each primers are indicated in 
Table. 3.
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Fig. 9. MS-275 enables epigenetic modification of the Runx2 P2 promoter, 
resulting in elevated expression. (A–C) WT and Runx2+/- primary osteoblasts 
were treated with vehicle or 3 µM MS-275 for 24 hr. (A) Runx2-I levels were 
determined by qPCR. (B) ChIP assays were carried out using antibodies against H4 
Ac, H3K9 Me, and MeCP. Chromatin fragments were PCR-amplified with primers 
for Runx2. (C) MSP analysis of the Runx2 promoter region. M and U represent 
amplification of methylated and unmethylated alleles, respectively. Bottom panel: 
Quantitation of MSP band density for unmethylated genes (dark gray bar) and 
methylated genes (light gray bar). (D) Digested or non-digested bands of Runx2 P2 
promoter luciferase reporter vector after HpyCH4IV endonuclease treatment, to 
confirm in vitro hypermethylation status. Methylation on the cytosine residue was 
carried by M.SssI CpG methyltransferase. (E–F) Runx2 promoter activity was 
assessed by luciferase reporter activity of (E) unmethylated promoter construct and 
(F) hypermethylated promoter. WT mouse calvarial cells were transfected with a 
Runx2 P2 promoter reporter construct, followed by the indicated dose of MS-275 
treatment for 24 hr. *P<0.05, **P<0.01, Student’s t-test.
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Fig. 10. Global levels of histone modifications. Histone samples were collected 
after 3μM MS-275 treatment to WT and Runx2+/- primary calvarial cells. Primary 
mouse calvarial cells were cultured with or without 3 μM MS-275 for 24 hrs and 
general levels of histone modifications were detected by immunoblot. Histone 3 
and beta-actin were used as loading controls. The bands of ß-actin were detected as 
a loading control.
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MS-275 accelerates osteoblast differentiation by activating proliferation 
and inhibiting apoptosis 
As we showed in Fig. 5, MS-275 induced Runx2 acetylation, thereby 
generating the activated form of Runx2, which positively regulates cell 
proliferation and differentiation. Previously, we showed that proliferation of 
osteoblast precursor cells in osteogenic front regions is a critical mechanism 
underlying suture closure (55). Furthermore, several reports suggest that suppression 
of HDAC1 increases cell proliferation and global protein synthesis in osseous cells 
(45,56). Because MS-275 is a member of selective class I HDAC inhibitors, we 
expected that treatment of MS-275 would improve proliferative activity of calvarial 
cells and affect osteoblast differentiation. Therefore, we performed RNA-seq to 
investigate the action of MS-275 on fetal calvaria and assess their transcriptomic 
response. GO term analyses revealed that administration of MS-275 affected 
various biological processes (Fig. 11A). Enrichment for GO terms associated with 
chromatin modification (GO:0016568), skeletal development (GO:0001501), and 
regulation of proliferation (GO:0042127) support previously characterized roles of 
MS-275. The Venn diagrams shown in Fig. 11B show 4127 up-regulated genes and 
6057 down-regulated genes (95% confidence, Student’s t-test), of which 430 up-
regulated and 218 down-regulated genes overlapped between E17.5 WT and 
Runx2+/- calvaria (Fig. 11B). Table 5 shows representative hallmark genes, grouped 
according to biological process. In general, genes related to bone formation and 
proliferation were up-regulated, whereas genes related to apoptosis were down-
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regulated. Firstly, we examined the in vitro effects of MS-275 on process of 
osteoblast differentiation. Expression levels of bone marker genes were elevated, 
indicating that MS-275 treatment rescued gene expression in Runx2+/- cells (Fig. 
12A). We investigated the early stages of osteoblast differentiation using ALP 
staining. MS-275 potentiated ALP activity in a dose-dependent manner in both WT 
and Runx2+/- cells. ALP staining levels were lower in Runx2+/- cells than in WT cells, 
but were increased by a high dose of MS-275: specifically, the staining level in 
Runx2+/- cells exposed to 6 μM MS-275 were similar to those of vehicle-treated 
WT cells (Fig. 12B). In accordance with the elevated ALP activity, MS-275 also 
increased calcium deposition, as determined by Alizarin Red S staining, which can 
show the late stages of osteoblast differentiation (Fig. 12C). These results are 
consistent with our assumption that MS-275 would compensate for the delayed 
differentiation potency of Runx2+/- cells.
Next, we examined the effects of MS-275 on cell proliferation. Expression 
levels of proliferation marker genes were slightly elevated, as shown in Table. 1. 
Notably, expression of β-catenin (Ctnnb) and Cyclin D1 (Ccnd1) (Fig. 13A) is 
linked with suture closure (57). Immunohistochemistry revealed elevated expression 
of cell proliferation marker protein in the osteogenic front of calvaria of MS-275–
treated newborn mice (Fig. 13B). Moreover, administration of a low dose of MS-
275 stimulated cell growth of primary osteoblasts (Fig. 13C). These observations 
corroborate our speculation that MS-275 promotes cell proliferation, thereby 
accelerating the process of suture closure. These findings supported the RNA-seq 
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results indicating that MS-275 exerts a positive effect on bone formation. Moreover, 
by selecting genes with high significance (P<0.05, 95% confidence) from among 
118 genes involved in apoptotic processes, including those involved in cell death 
and DNA damage response, we found that MS-275 exerted an inhibitory effect on 
apoptosis. This is reasonable because this observation corresponds to the observed 
promotion of proliferation; moreover, it is consistent with previous reports that 
elevation of apoptosis during development leads to delayed suture closure and 
acrania-like craniofacial deformities (58,59). Collectively, these data indicate that the
Runx2 stimulating effect of MS-275 can increase osteoprogenitor cell number in 
suture space by stimulating proliferation and stimulate further differentiation of 
these cells in Runx2+/- mouse calvarial cells and tissue.
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Fig. 11. Next Generation Sequencing (NGS) analysis shows effects of MS-275
on osteoblast proliferation and differentiation. (A) Gene ontology (GO) 
pathway analysis of E17.5 mouse calvaria of both genotypes that were injected in 
utero with MS-275, in comparison with vehicle-injected fetal calvaria. GO 
biological process are depicted according to p-values. (B) Venn diagrams of genes 
up- and down-regulated following MS-275 treatment in WT (solid line) and 
Runx2+/- (dotted lined) calvaria. Regulated genes from (A) were counted and 
classified.
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Fig. 12. MS-275 induces osteoblast differentiation. (A) Relative expression of 
bone marker genes was assessed based on qPCR analysis from E17.5 mouse 
calvaria to validate the RNA-seq results. The level of osteoblast differentiation was 
estimated by (B) ALP staining and (C) Alizarin red S staining assay. Primary cells 
were cultured in osteogenic media after 24 hr culture with the indicated 
concentration of MS-275. Stained areas are magnified beside the panel. All 
experiments were performed in triplicate. Veh.= Vehicle, MS.= MS-275. *P<0.05, 
**P<0.01, ***P<0.001, Student’s t-test.
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Fig. 13. MS-275 stimulates cell proliferation (A) Relative expression of 
proliferation marker genes from E17.5 mouse calvaria to validate the RNA-seq 
results. (B) Ki-67, a marker of proliferation, was detected at the osteogenic front 
region of P0 mouse calvaria (Scale bar, 50 µm). The region of calvarial bone is 
marked with dotted line. The osteogenic front region is magnified in box inset. 
Arrows indicate positively stained cells. (C) Proliferation assay results from 
primary mouse calvarial cells. Following treatment with different doses of MS-275 
for 24 hr, proliferation rates were evaluated after additional culture for 1 day and 6 
days. All experiments were performed in triplicate. Veh.= Vehicle, MS.= MS-275. 
*P<0.05, **P<0.01, ***P<0.001, Student’s t-test.
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Discussion
Previously, it was suggested that a threshold level of RUNX2 is required 
for the normal skeletal development (39), and that RUNX2 is deficient in human 
CCD patients and Runx2+/- mice (11). In this study, we tested the hypothesis that 
restoration of Runx2 activity by MS-275 treatment could prevent development of 
CCD-like phenotypes in Runx2+/- mice. Indeed, our results show that fetal 
administration of MS-275 during early skeletal development rescued Runx2+/- mice 
from CCD-like phenotypes related to development of the cranial suture, mandible, 
and clavicle (Fig. 1). Rescuing CCD-like phenotypes could be more effective when 
we adjust the initiation stage, dosage and frequency of drug treatment with 
pharmacokinetic analysis. However, since we administrated chemicals in utero, 
there was a limitation of using Runx2+/- mice for this study; we could not rule out 
the maternal effects on the embryos during pregnancy. To overcome this limitation, 
we showed double fluorescence labeling assay accompanied with organ culture 
system. In this study, we showed MS-275 exerted a much stronger effect on 
intramembranous rather than endochondral bone formation. In contrast to the 
prominent effect in flat bones, long bone development was neither significantly 
perturbed by Runx2 deficiency nor significantly improved by MS-275 (Fig. 3). 
Clavicles develop by both endochondral (lateral part) and intramembranous 
(medial part) bone formation processes(41). In hypoplastic clavicles, the medial part 
is usually missing. We found that MS-275 treatment primarily restored the medial 
part of the clavicles in Runx2+/- mice, indicating that intramembranous bone 
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formation is more sensitive to the restoration of Runx2 function by MS275 
treatment (Fig. 2). Compared to other membranous bones like calvaria and 
mandible, MS-275 did not restore clavicle formation that markedly. This may be 
because clavicles are among the earliest bones to develop (60), whereas we initiated 
MS-275 administration at 14.5 d.p.c., potentially too late to recover clavicles. Thus, 
earlier administration might be preferable for this purpose. These results 
demonstrated that genetic insufficiency of a gene due to a single-allele loss-of-
function mutation can be rescued by increasing protein activity or stability with 
specific modulators. This approach could also be applied to the treatment of other 
single-gene genetic disorders.
Next, we addressed the mechanism underlying the effects of MS-275 on 
CCD-like phenotypes. First, we are suggesting MS-275 has a role in Runx2 post-
translational modification because it can acetylate Runx2, generating the 
functionally activated form. As expected, acetylated Runx2 was stabilized and 
spared from degradation, and both its abundance and transactivating activity 
increased (Fig. 5-7). Nonetheless, it remains possible that the level of Runx2 
protein was indirectly elevated resulting from an increase in Runx2 mRNA 
expression in response to MS-275 treatment, as shown in Fig. 9A. Therefore, to 
rule out this background, we carried out tag-detection system in immune blot after 
overexpression of MYC-tagged-Runx2 (Fig. 5D). Previous study also 
demonstrated by using overexpression of tagged-Runx2 system that HDAC 
deacetylates Runx2 and HDIs increases its acetylation (14). These results indicate 
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that MS-275 can enhance Runx2 protein activity in the absence of transcriptional 
upregulation of endogenous Runx2. Second, MS-275 can modify the epigenetic 
landscape. Specifically, the drug decreased the methylation level of the CpG island 
in the Runx2 promoter 2, thereby stimulating Runx2 expression. This observation is 
consistent with previous reports that MS-275 promotes both histone acetylation (by 
inhibiting HDAC) and CpG demethylation (by repressing DNA methyltransferase)
(61). In aspects of histone modification, our results of ChIP assay and immune blot 
assay were also comparable with previous study, which demonstrated marked 
histone modification dynamics during osteoblast differentiation (Fig. 9B, Fig. 10). 
In the process of osteogenesis, promoter region of Runx2 experienced elevated H3 
and H4 acetylation and reduced H3K9, H3K27 methylation whereas global level of 
those hall marks were not changed (48). Collectively, these changes promote Runx2
transcription (Fig. 9A). Together with post-translational modification of Runx2 
protein, the positive effect on transcription may be sufficient to reach the threshold 
Runx2 level required to overcome genetic haploinsufficiency. 
What, then, is the functional consequence of Runx2 activation in the early 
skeletogenesis? Our RNA-seq results indicated that MS-275 strongly stimulated 
the expression of osteoblast marker genes, as was well known from previous 
studies (27). In addition, we observed significant upregulation of proliferation-
related genes and downregulation of apoptosis-related genes (Fig. 11, Table. 5). 
Previously, we showed that many HDIs can stimulate Runx2 activity (14). These 
observations are correlated with study of Schroeder and colleague. They showed 
57
increased ALP activity in calvarial tissue cultured media after MS-275 treatment 
and suggested MS-275 has a role in enhancing Runx2 transcriptional activity (28). In 
this study, we found that MS-275 has a clear therapeutic effect on CCD. This might 
be explained in any of several ways. First, the differences in the effects of MS-275 
may be due to its distinct specificities on HDAC1 and 3. MS-275 preferentially 
inhibits HDAC1 and 3 with IC50 of 0.51 and 1.7μM correspondingly. Previous 
reports showed that HDAC1 binds to promoters of the bone marker genes osterix 
and osteocalcin to repress their expression (62). In addition, HDAC3, a well-known 
transcriptional co-repressor of Runx2, works as a negative regulator of lineage-
committed osteoblasts by binding to NFATc1, Zfp521, TCF, and Runx2 (25). 
Collectively, these facts could explain, at least in part, the successful therapeutic 
effect of the class I–specific inhibitor MS-275. Second, marked stimulating activity 
toward cell proliferation might cause distinct CCD recovery effects. MS-275 
presented effective stimulation on expression of proliferation marker genes and
proliferation process (Fig. 13, Table 5). In the previous study, we found that MS-
275 stimulates bone formation by interaction with Dhx36 (27), also known that it has 
critical roles in process of cell proliferation (63). Therefore, we deduced that Dhx36-
mediated signaling might be participated in highly triggered cell proliferative 
activity through MS-275 administration. Considering significance of proliferation 
of osteoblast progenitor cells in calvarial suture region during development (55), it 
could be the critical distinction of MS-275 treatment toward CCD.
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Based on our findings and previous reports we conclude that the 
combined functions of MS-275 are responsible for the effects; Runx2 activation 
through PTM and transcriptional activation of Runx2 via epigenetic regulation (Fig. 
14). To reach comparable therapeutic effect with a single mechanism, just by PTM 
or by epigenetics, the therapeutic dosage might be increased higher to generate 
more side effects. The dosage of MS-275 in this study is much less than one tenth 
of other experiments (64) and the litter number of MS-275 treated mice was 
comparable that of untreated control. These results indicate combination of both 
mechanisms synergized to enhance Runx2 specific activity of the agent with a 
lower dose. In addition, the enhanced Runx2 function by MS-275 stimulates 
osteoblast proliferation and differentiation processes. However, we must be
cautious when interpreting the relationship between cell proliferation and MS-275 
since it also has anti-proliferative effects and apoptosis-inductive properties as an 
anti-cancer reagent. However, many studies show that the effect of HDIs including 
MS-275 on cell proliferation is concentration-dependent: in general, they promote 
proliferation at low dose but inhibit growth at high dose (28). Although we could not 
observe any skeletal malformation as a side effect of HDI administration, some 
kinds of HDIs, valproic acid and trichostatin A (TSA) for instance, were reported 
as teratogenic reagents for developing mouse skeletons causing embryonic skeletal 
malformation including vertebral or rib fusions at high dose administrations (65). 
Thus, more extensive- toxicological study would be required to apply HDIs in 
clinical field.
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As regulation of Runx2 activity is of tremendous interest from the 
standpoint of developing therapeutic agents against skeletal diseases, our findings 
have important medical implications. Notably, we demonstrated that MS-275 could 
compensate for genetic insufficiency of Runx2 in Runx2+/- mice. Therefore, the use 
of this drug thus represents a promising chemo-preventive strategy for a genetic 
disease, CCD, especially if it can be diagnosed before birth. MS-275 also holds 
tremendous potential as a therapeutic agent for diseases involving the Runx2 gene, 
including many bone disorders. Thus, our results provide a novel experimental and 
theoretical basis for developing therapeutic agents against CCD and other skeletal 
diseases.
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Fig. 14. Mechanism of Runx2 activation by MS-275. MS-275 regulates Runx2
expression via two mechanisms. 1) Stabilization of Runx2 protein through post-
translational modification (PTM), which induces Runx2 acetylation and protects 
Runx2 from ubiquitination. 2) Epigenetic activation of the Runx2 promoter region 
via alteration of the epigenetic landscape. MS-275 activates the Runx2 promoter by 
modifying chromatin structure from heterochromatin to euchromatin by increasing 
histone acetylation and decreasing CpG and histone methylation. HAT= Histone 
Acetyl Transferase, Ac= Acetylation. 
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IV. Part II.
RNA-seq. data analysis identifies MS-275 as an activator of 
osteoblast differentiation of Runx2+/- mouse calvarial cells
Abstract
The genetic mechanisms regulating osteoblasts differentiation is still not 
fully understood. Previously, we found that Histone deacetylase inhibitor (HDI), 
MS-275 rescues CCD phenotypes of Runx2+/-mice and delayed osteoblast 
differentiation of Runx2+/- mouse calvarial cells. Herein, we performed an RNA-
seq on WT and Runx2+/- mouse calvarial cells either with or without MS-275 
treatment and identified a Runx2 specific gene expression signatures and MS-275 
dependent changes on biological processes. Furthermore, bioinformatics analysis 
on the RNA-seq. data identified a group of genes regulating cell proliferation and 
osteoblast maturation of which expressions were altered by Runx2
haploinsufficiency and recovered after MS-275 treatment. Concordantly, these 
genes are consistent with our idea about the role of MS-275 since they are known 
to interact with Runx2 to regulate process of bone formation. Our study provide 
insight into the understanding of the correlation between the pathological 
consequence of Runx2 deficiency and therapeutic effect of histone deacetylase 
inhibition through facilitating osteogenesis. 
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Introduction
During skeletal development, expressions of many genes are highly 
regulated and thus result in specific cell phenotypes depend on differentiation stage. 
The expression pattern of the genes changed when the intracellular environment 
changes. The altered gene expression means a change in cell function, which 
changes the cell fate.
Bone formation is conducted by two kinds of development processes; 
Endochondral ossification and intramembranous bone formation. Both processes 
require differentiation of mesenchymal stem cells (MSCs) into chondrocytes (in
case of endochondral bone formation) and/or osteoblasts. Cells in endochondral 
bone development would be involved in mesenchymal condensation to form 
cartilage anlagen. To occur these events, several chondrocyte-specific genes are 
expressed including Sox9, Gli3, and Hoxa13. Sox9 plays a crucial role in cartilage 
development by permitting transcript of aggrecan (Acan), collagen type II, collagen 
type IX, and cartilage oligomeric protein (Comp). According to these gene 
expressions, chondrocytes in the growth plate proliferate and undergo extracellular 
matrix (ECM) deposition and hypertrophy to promote bone lengthening. At the late 
stage of the endochondral bone formation, hypertrophic chondrocytes down-
regulate expression of collagen type II and start to secrete collagen type X, and 
ossify the ECM with expression of Runx2, Osterix, Msx2. As maturation progresses, 
hypertrophic chondrocytes stimuli production of vascular endothelial growth factor 
(Vegf), which trigger vascularization and metalloproteinases (Mmps), which 
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support ossified cartilage matrix turnover. Through these series of cellular 
maturation processes develop into long bones comprise the appendicular skeleton, 
vertebrae, facial bones, and the lateral parts of clavicles. 
On the other hand, cells undergo intramembranous ossification, 
differentiate into osteoprogenitor cells after aggregation of mesenchymal cells into 
condensation centers. In this period, cells permit transcription of Bmp2, Bmp4, 
several Wnt ligands, β-catenin, and Fgf2 for proliferation. Subsequently 
differentiated into pre-osteoblasts and matured to osteoblasts that act as a critical 
player in osteogenesis. Those osteogenic cells generally express collagen type I, 
osteopontin (Opn), alkaline phosphatase (Alp), osterix (Osx), Dlx5 and osteocalcin
(Oc) to secrete ECM components, osteoids, and uncalcified matrix, which 
ultimately calcifies as mineral slats are deposited on it, thereby forming 
intramembranous bone. Throughout these developmental steps, intramembranous 
ossification gives rise to the flat bones constitutes the cranium and medial clavicles.
Expression of genes during early stage of bone formation is mostly 
influenced by Runx2, the master transcription factor in osteogenesis. Runx2 plays a 
role in controlling a complex gene-transcription system during osteoblast 
differentiation. It upregulates the expression genes involved in osteoblast lineage-
specific group such as Osx, Oc, and Bsp, and represses the non-osteoblast genes 
including MyoD (myogenic differentiation), and PPARγ(peroxisome proliferator-
activated receptor gamma) which are essential for myogenesis and adipogenesis, 
respectively. In addition, recently, transcriptional regulation by chromatin 
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remodeling has become as important mechanism as that by transcription factors. It 
has been reported in numerous studies that modulation of epigenetic landscape
could affect key transcriptional factors to determining gene expression and 
differentiation of mesenchymal stem cells. Epigenetic regulation refers to a change 
in chromatin structure, which is derived by the modification of histone proteins 
includes acetylation, methylation and phosphorylation. Epigenetic modulation is 
able to induce heritable changes in gene expression via modification of 
chromosomal structure other than alteration of the DNA sequence. Acetylation or 
deacetylation of histone has an important responsibility in the process of gene 
transcription which is regulated by a balance of the enzymatic activity of histone 
acetyltransferase (HAT) and histone deacetylase (HDAC). Dynamic equilibrium of 
the two distinct enzymatic activities are critical for the activation of transcription 
and regulation of gene expression in eukaryotic cells.
A number of studies investigated the biological role of chemical 
compound, which inhibit HDAC activity for their possible therapeutic effects.
HDAC Inhibitors (HDIs) transform histone to hyper-acetylated form, which result 
s in the relaxation of the DNA structure, which in turn activates the expression of 
specific genes. Previously, we demonstrated that Class I HDI, MS-275, recovered 
hypoplastic bone formation of Runx2+/- mice and enhanced osteoblast 
differentiation in Runx2+/- mouse calvarial cells. Moreover, Dudakovic et al. 
revealed that HDI stimulated osteoblast differentiation by increasing Runx2
activity. These studies have highlighted the regulatory role of HDI towards Runx2 
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transacting activity and Runx2 transcription. However, the entire genetic scope of 
Runx2 haploinsufficiency and MS-275 administration remains largely unknown.
Herein, we have characterized the gene expression profile by RNA-sequencing in 
WT and Runx2+/- mouse calvarial cells which were cultured with or without MS-
275 treatment. Analysis of this data indicated that dynamic changes in the gene 
expression pattern due to the genetic background and/or chemical treatment are 
related to the biological characteristics of cells and it would be an important tool to 
explain the biological phenomenon.
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Results
Differentially expressed genes in each cellular context were discovered 
by RNA-sequencing.
Although Runx2 is a well-known central regulator of bone formation and 
MS-275 have also reported as activator of osteoblast differentiation, only a small
number of target genes have been identified. To examine genome-wide gene 
expression pattern according to the physiological environment, Runx2-deficiency 
and/or chemical treatment, we carried out RNA- sequencing (RNA-seq.) technique. 
There were 22.37 million short reads and 28,957 references of genes to analyze 
RNA expression profile. After quality filtering, approximately 8,800 differentially 
expressed genes were detected in each group. The genes were filtered using P-
value < 0.05 threshold that produced 441, 2,486, 1,940, and 1,273 differential gene 
sets for WT vs WT with MS-275 treatment, WT vs Runx2+/- both with vehicle 
treatment, Runx2+/- vs Runx2+/- with MS-275 treatment, and WT vs Runx2+/- both 
with MS-275 treatment, respectively. Each gene was categorized according to its 
fold change value (Table 6). Heat-map analysis revealed that there are many genes
that are regulated expression in various manner according to each context of cells.
Therefore, we clustered genes based on the expression pattern in the genetic 
background and physiological context (Fig 15).  
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Total number of genes 28,957 28,957 28,957 28,957
Detected gene expression 8,211 8,140 8,119 7,580
P-value < 0.05 441 2,486 1,940 1,273
2 - 5 fold upregulated 119 196 195 141
5 - 10 fold upregulated 35 12 13 19
> 10 fold upregulated 65 2 5 28
2 - 5  fold downregulated 65 34 21 60
5 -10  fold downregulated 18 147 0 3
> 10 fold downregulated 9 1 0 0
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Fig 15. Heat-map analysis of the normalized expression level of the 194 DEGs 
for each group. 194 gene expression patterens for WT and Runx2+/- genotype 
mouse calvarial cells cultured with or without MS-275 treatment. Genes were 
clustered according to their distinct expression pattern. Gene expression level was 
measured by RNA-seq. analysis with value expressed as Reads Per Killobase of 
transcript per Million mapped reads (RPKM). Increased and decreased levels of 
gene expression are shown in blue (decreased) and red (increased) color, 
respectively. 
69
Runx2 haploinsufficiency causes dynamic alteration of gene expression.
As reported previously, Runx2 heterozygous null mice showed 
phenotypes of Cleidocranial dysplasia and Runx2+/- cells exhibited delayed 
osteoblast differentiation. To gain insight into molecular properties of Runx2, we 
constructed scatter plot to recognize the expression patterns of each comparative 
groups. Firstly we set the value of log2(Runx2
+/- MS/Runx2+/- veh.) as an X-axis to 
measure the expression differences of MS-275 treatment toward vehicle treatment 
in Runx2+/- cells and the log2(Runx2
+/- veh./WT veh.) as an Y-axis to compare 
between WT and Runx2+/- cells in vehicle treated group. Analysis of the RNA 
expression plot revealed that 4399 genes are down-regulated in WT versus Runx2+/-
and 4440 genes are up-regulated (Fig. 16A). We deduced that these differentially 
expressed genes could provide the clue of pathological effects of Runx2-deficiency 
which cause imperfect differentiation into osteoblasts. To identify biological 
processes changed by Runx2 haploinsufficiency, we subjected the differentially 
expressed genes (DEGs) to gene ontology (GO) analysis of biological process. GO 
term analysis showed that genes down-regulated by Runx2-deficiency are 
comprised in cell activation, angiogenesis, cell communication and bone 
formation-related processes such as ossification, ossification, embryonic skeletal 
system development. Up-regulated genes in Runx2+/- samples were enriched for 
processes associated angiogenesis, chromosome segregation, cell signaling and 
osteogenesis-related processes including osteoblast differentiation and embryonic 
skeletal system development (Fig 16B). These results show that how Runx2 
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haploinsufficiency influences general gene expression and biological processes.  
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Fig. 16. The pattern of gene expression and biological process are altered by 
Runx2 haploinsufficiency in mouse calvarial cells. (A) Scatter plot depicting the
correlation between relative gene expression value of Runx2+/- calvarial cells with 
vehicle treatment versus Runx2+/- cells with MS-275 (X-axis) and Runx2+/- cells 
with vehicle versus WT vehicle (Y-axis). (B) Analysis of gene ontology of 
biological functions for down-regulated (blue-colored bar) and upregulated (red-
colored bar) genes from Runx2+/- with vehicle versus WT with vehicle RNA-seq.
data sets. The value of log2(fold change) is used to create 2D plots.
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MS-275 treatment have affected gene expression pattern on Runx2+/-
mouse calvarial cells 
Since we eager to explore the phenomenon that altered expression of the 
genes in disease model were restored through HDAC inhibition, we focused on 
quadrant II and quadrant IV of expression plot in Fig. 16. Analysis of gene sets in 
these quadrant we were able to unravel the biological relevance of the MS-275 
treatment and Runx2 haploinsufficiency. 336 Genes in the quadrant II, their 
expression was increased in Runx2+/- and decreased after MS-275 treatment. On the 
other hand, 381 genes in quadrant IV, their expression was reduced in Runx2+/- cells 
and rise in MS-275 treated group (Fig. 17A). To further explore the correlation 
between genes in each quadrant and biological process, we performed functional 
annotation using Gene-Set Enrichment Analysis (GSEA). Analysis of Gene 
Ontology (GO) terms which associated with significantly changed genes were 
indicated in Fig. 17B. Genes in quadrant II yielded GO terms of proliferation, bone 
development, and ossification. Gene in quadrant IV associated GO terms of 
immune response, angiogenesis, bone development, and biomineral formation.
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Fig. 17. Treatment of MS-275 modifies gene expression pattern in Runx2+/-
mouse calvarial cells. (A) Expression plot of RNA-seq. results. Relative gene 
expression value of Runx2+/- calvarial cells with vehicle treatment versus Runx2+/-
cells with MS-275 (X-axis) is plotted on the Runx2+/- cells with vehicle versus WT 
vehicle (Y-axis) site of correspond gene. (B) Analysis of gene ontology of 
biological functions for downregulated (blue-colored bar) and upregulated (red-
colored bar) genes from Runx2+/- with vehicle versus WT with vehicle RNA-seq.
data sets. The value of log2(fold change) is used to create 2D plots.
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Genes showing significant patterns in Runx2 haplodeficiency and by 
MS-275 treatment could be a therapeutic marker of cleidocranial 
dysplasia. 
A number of enriched GO terms were related to osteogenesis and skeletal 
development (Fig. 17B). As we investigated the genetic mechanism that delayed 
osteogenesis was restored through MS-275 treatment, narrow down to target 
associated with bone formation which overlapped GO term of genes involved 
quadrant II and quadrant IV in RNA expression plot (Fig. 17). We detected 7 bone 
development-related genes from quadrant II; Acan, Fbn2, Sfrp2, Col11αI, Igfbp3, 
Col2αI, Col8αII, 8 genes from quadrant IV; Junb, Ecm1, Csf1, Msx2, Acp5, Ptgs2, 
Grem1, Cd24a (Fig. 18A, B, Table. 7). Among those 15 candidate genes, we 
selected 4 of the most significant genes, Acan, Fbn2, Ifgbp3, and Csf1 according to 
relative P-values (Fig 18C). In addition, we examined the recovery levels of 
candidate genes how closely the genes recovered to the normal trait after MS-275 
treatment (Fig. 18D). To validate the actual gene expression level of the RNA 
samples correspond to the RNA-seq. results, we carried out quantitative real-time 
PCR (Fig. 18E). We have confirmed that the RNA expression level of all target 
genes is consistent with the patterns seen in data of RNA-seq. analysis. 
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Fig. 18. Target gene selection using RNA expression plot and P-value. (A, B) 
Expression plot of RNA-seq. results. Relative gene expression value of Runx2+/-
calvarial cells with vehicle treatment versus Runx2+/- cells with MS-275 (X-axis) is 
plotted on the Runx2+/- cells with vehicle versus WT vehicle (Y-axis) site of 
correspond gene. Genes expressed higher level in Runx2+/- cells than WT and 
decreased with MS-275 plotted on graph (A). Genes exhibited reduced expression 
pattern in Runx2+/- and increased with MS-275 treatment were plotted on graph (B).
(C) The 15 candidates of target genes are plotted according to their relative p-
values. (D) RNA expression plot with X-axis of log2(Runx2
+/- MS-275 / Runx2+/-
vehicle) and Y-axis of log2(Runx2
+/- MS-275 /WT vehicle) which can show
recovery levels of gene expression in Runx2+/- cells with MS-275 treatment. (E) 
Expression patterns of each target gene were validated by quantitative real-time 
PCR.
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Acan 11.1744329 4.65E-07 0.001892 0.455231286 0.000384 0.051473
Fbn2 9.025270758 4.40E-05 0.008946 0.598631579 0.001549 0.061684
Sfrp2 6.106864869 0.000395 0.015497 0.569015007 0.035411 0.172115
Col11a1 2.599769388 0.000801 0.019357 0.748048169 0.006383 0.088799
Igfbp3 2.741899084 0.000848 0.019624 0.227494826 0.002749 0.069889
Col2a1 1.570133121 0.006057 0.047308 0.546726557 0.068149 0.239512
Col8a2 1.840067906 0.00407 0.038739 0.313295583 0.006669 0.090191
Junb 0.547682533 0.032842 0.125231 3.94599849 0.00319 0.072944
Ecm1 0.482472949 0.000974 0.020287 2.069059038 0.033459 0.168035
Csf1 0.564773069 0.000791 0.01922 3.38933912 0.001989 0.065489
Msx2 0.615819135 0.001849 0.027167 1.677436818 0.036422 0.174623
Acp5 0.510788272 0.145461 0.317653 10.96126466 0.003288 0.073349
Ptgs2 0.195628973 0.0027 0.032745 3.481745272 0.02182 0.138157
Grem1 0.452214895 0.000777 0.018983 2.630160595 0.004725 0.080111
Cd24a 0.435330391 0.001007 0.020684 2.675680921 0.005688 0.084185
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Fig. 19. The string diagram shows the predicted protein-protein interactions 
of the 5 queries (Runx2, Acan, Csf1, Fbn2, and Igfbp3) of differentially 
expressed genes. Colored nodes in string diagram represent query proteins and 
their reported interactions with multiple nodes. Edges represent protein–protein 
associations, and different colors of the edges represent different associations. The 
known interactions were found from curated databases (blue) or experimentally 
confirmed (purple); the predicted interactions were suggested by gene 
neighborhood (green), gene fusions (red), or gene co-occurrence (dark blue); and 
other protein–protein associations were suggested by text-mining (yellow–green), 
co-expression (black), or protein homology (gray).
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Discussion
Through comprehensive gene expression analysis of mouse calvarial cells 
by RNA-seq., we describe pathological effect caused by Runx2 haplodeficiency 
and physiological consequences of HDAC inhibition on osteoblast. Genes cluster 
into expression pattern according to Runx2 haploinsufficiency and MS-275 
treatment related with broad range of biological function including angiogenesis, 
cell proliferation, ossification, and skeletal development. These results reflect that 
importance of Runx2 in osteogenesis and role of MS-275 as an activator toward 
osteoblast differentiation. Our study identified new Runx2-regulated genes (Acan, 
Fbn2, Igfbp3 and Csf1) that found responsibility in delayed osteoblast 
differentiation in Runx2+/- cells, and more critically, shown possibility of being a 
marker for therapeutic efficacy because their altered expression patterns were 
recovered to those of WT level when MS-275 was treated.   
The biological characteristics of the target genes are all related to the 
differentiation and maturation of osteoblasts. Acan (aggrecan) is a member 
belonging to the aggrecan/vesican proteoglycan family. An Acan act as major 
player in cartilage formation by constituting ECM and binding to calcium ion, 
which is also an important mechanism for the osteoblast maturation. Genetic 
defects in Acan is reported that it bring Osteochindritis Dissecans, Osteoarthritis 
and Spondyloepimetaphyseal dysplasia. Fbn2 is a protein coding gene, encoding 
Fibrillin-2 which is structural components of extracellular calcium-binding 
microfibrills. Associated human diseases with Fbn2 are Contractural 
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Arachnodactyly and Macular Degeneration which affect connective tissues and 
neuronal tissue respectively. The reason that defects in Fbn2 causing these diseases 
might it involved in several signaling process such as phospholipase-c pathway and 
ERK signaling. Furthermore, fibrillin was known to be a factor controlling the 
maturation of osteoblast by regulating TGF-β and BMP signaling (66,67). Igfbp3 is 
one of the member of insulin-like growth factor binding protein (IGFBP) family. 
After formation of ternary complex of IGFBP protein, it circulates in the plasma 
and protects insulin-like growth factors (IGFs) from degradation. Igfbp3 is known 
to be regulated by Runx2-dependent expression and is affected by FGF signaling 
during tooth development (68). Lastly, Csf1 (colony Stimulating Factor 1) is the 
gene encoding cytokine that regulates the function of macrophages. It is well-
known factor as a regulator of osteoclast proliferation and differentiation, bone 
resorption and is also essential for normal skeletal development (69). It is highly 
corresponding that the expression of genes related to osteoblast maturation changes 
with the haplodepletion of Runx2 and the treatment of potential therapeutic reagent, 
MS-275.  
Through analysis of bioinformatics data, we could find a novel level of 
understanding of the compensated differentiation effect via HDAC inhibition 
which conducted previously (30). Our study showed how the deficiency of Runx2 
affects the overall genes in cells and how those genes changed by MS-275 
treatment. Some identified target genes which showing dynamically shifted 
expression could serve as a critical clue for understanding the pathological 
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mechanisms of the disease and the pharmacological effect of the MS-275 (Fig. 19). 
However, the results what we have identified are only a section of the biological 
event. Further experimental study is required to figure out whether significantly 
altered gene expressions were the cause or the result of the phenomenon. If we find 
a hidden link between the CCD and HDAC inhibition, the impact of our study 
investigating the genome-wide gene expression of primary mouse calvarial cells 
classified by genotype and HDI treatment sets an outline for understanding genetic 
insight of bone biology.  
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V. CONCLUSION
Runx2 is a key transcription factor in the osteogenesis and skeletal 
development. Controlling of bone formation has consistently been a major concern 
in the clinical field dealing skeletal diseases. In this study, we focused on 
mitigating phenotypes of CCD which caused by Runx2 haploinsufficiency. 
In the Part I, firstly I tried animal experiment to examine therapeutic 
effect of histone deacetylase inhibition by using MS-275. In utero administration of 
MS-275 showed a dramatic recovery effect on the Runx2+/- fetus. Subsequently, I 
found that MS-275 acetylates Runx2 transcription factor and increase its 
transactivating activity which ultimately leads to the promotion of osteoblast 
differentiation. Furthermore, I identified more that MS-275 could also stimulate 
Runx2 transcription through epigenetic regulation. Based on these findings and 
previous studies I define that the combinated functions of MS-275 as follows; 
activates Runx2 protein through process of PTM and increase transcription of 
Runx2 via mechanism of epigenetic regulation (Fig. 14). These functions of MS-
275 stimulate biological procedures of osteoblast proliferation and differentiation. 
In the Part II, I demonstrated that genome-wide gene expression is altered 
dynamically in the context of Runx2 haploinsufficiency and MS-275 treatment. 
Although, it was well known that Runx2 regulate bone marker genes and MS-275 
has characterized as activator of osteoblast differentiation, only a few genes were 
acknowledged. I get the data set of approximately 8,800 differentially expressed 
83
genes (DEGs) by conducting RNA-seq. analysis. After clustering genes by 
expression pattern, I found 4 significant target genes (Acan, Fbn2, Igfbp3, and 
Csf1) which expression were altered in Runx2+/- cells and recovered in MS-275 
treated cells. With this study, I suggest that these RNA-seq. data would provide 
genetic insight into Runx2 haplodeficiency and histone deacetylase inhibition in 
mouse calvarial cells. The newly detected target genes could serve as a marker 
which able to verify therapeutic efficacy of MS-275 toward CCD. 
Because regulation the activity of Runx2 is one of marvelous interest from
current position of developing therapeutic drugs toward skeletal-related diseases,
the findings from this study have significant medical implications. Remarkably, I
exhibited that MS-275 is able to complement the disease phenotypes due to genetic 
deficiency of Runx2 in both of Runx2+/- mice and Runx2+/- cells. In conclusion, the 
use of this agent thus works as an innovative chemo-preventive strategy for CCD.
Furthermore, inferring though RNA-expression profile, MS-275 has great potential 
as a therapeutic agent for skeletal disorders not only associated with the Runx2
gene but also other genes related skeletal disorder such as Acan, Fbn2, Igfbp3 and 
Csf1. Therefore, my results support a novel theoretical insight and experimental 
basis for developing medical agents against CCD and other bone-related diseases.
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히스톤 탈아세틸화 효소 억제에 의한 뼈 이상 회복 기전 연구
서울대학교 대학원 치의과학과 분자유전학전공
(지도교수 류 현 모)
배 한 솔
Runx2/Cbfa1/AML3는 초기 골 분화 과정에서 핵심적인 역할을
하는 전사인자이다. Runx2 유전자의 전사나 단백질의 합성후수식 조절
기전에 저해되어 비정상적인 발현이 일어날 경우, 여러 골 질환을 야기
하는 것으로 보고되어 있다. 본 연구에서는 두개쇄골이형성증
(Cleidocranial dysplasia; 이하 CCD)이라는 질환에 주목하여 약물을
처리하였을 때 증상 회복 여부를 분자생물학적 측면과 더불어 후성유전
학 측면에서 확인하고 검증하였다.
CCD 는 상염색체 우성 유전질환으로, RUNX2 유전자의
반수체부족성에 의해 발병하는 것으로 알려져 있다. 대부분의 CCD 
환자들의 주요 증상은 부진한 골격 발달로 인하여, 쇄골이 정상적으로
형성되지 않은 양상을 보이거나 두개골이 완전히 유합되지 않아
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정상인보다 큰 천문을 가진다는 것이다. 현재까지 골 발달과 골다공증
등의 분야에서 RUNX2 에 대해 많은 연구가 이루어졌지만 아직까지
CCD 증상을 치료할 수 있는 약물요법은 개발되지 않은 실정이다. 최근
보고된 연구에 따르면 동물모델에서 CCD 표현형을 나타내는 데에는
Runx2 mRNA 발현임계치가 존재한다고 한다. 우리는 이 연구 결과에
기반을 두어, 약물을 처리하여 정상적으로 기능하는 Runx2 의 양을
어느 수준까지 향상시킨다면 환자들의 CCD 증상을 완화할 수 있을
것이라 가설을 세우고 기존 연구에서 Runx2 의 발현 및 활성을
높여주는 것으로 규명한 약물, MS-275 (제 1 형 히스톤 탈아세틸화
효소 억제제)를 후보 약물로 선정하였다. 본 논문에서는 MS-275 를
동물모델 및 세포 모델에 처리하여 우리의 가설을 검증한 내용을 다루고
있으며 이를 통해 CCD 질환 치료제 개발의 기반을 마련하고자 하였다.
CCD 표현형을 나타내는 Runx2+/- 마우스의 태아에 MS-275
를 투약하였을 때 두개골의 유합 양상을 포함한 여러 골 기형이 정상 형
질에 가깝게 회복되는 것을 확인 한 바, 이를 시작으로 실험적 검증을
통해 MS-275의 CCD 표현형 마우스에 대한 약물 효과는 다음 두 기전
에 의하여 나타나는 것으로 설명할 수 있었다. (1) Runx2 단백질을 합
성후수식 조절 (단백질 아세틸화)을 통해 안정화시켜 전사인자로써의 역
할을 활성화시킨다. (2) 후성유전학적 조절을 통해 Runx2를 포함한 타
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골 마커 유전자들의 발현을 증가시킨다. 또한, MS-275는 조골세포의
증식을 촉진한다는 것을 동물 조직과 세포 수준에서 규명하였다. 이는
CCD 환자에서 골격 형성이 부진하게 이루어지는 증상이 골전구세포들
의 증식능 결함과 긴밀한 연관성이 있음을 시사한다. 
이후 RNA 염기서열 분석을 통해 약물을 처리한 조직 및 세포에
서 Runx2 반수체부족성 유전형이 되었을 때 발현이 증가하는 유전자
군과 감소하는 유전자 군으로 분류하여 각각의 유전자 군이 관여하고 있
는 생물학적 기전을 생물정보학적으로 분석함으로써 Runx2 유전자 결
핍에 의한 병인학적 현상을 유전자 수준에서 확인하였다. 한편으로는, 
MS-275를 처리하였을 때 발현양상이 정상형질 수준으로 되돌아가는
유전자 군을 확인함으로써 MS-275의 약리학적 효과를 확인할 수 있었
으며, 이들이 관여하는 생물학적 기전이 대부분이 세포의 증식, 조골세
포의 분화, 그리고 골격의 형성 및 유지에 관여하고 있음을 확인하고 앞
서 수행한 in vivo 및 in vitro 연구와 상응하는 결론을 얻을 수 있었다.
본 논문에서는 MS-275라는 히스톤 탈아세틸화 효소 억제제가
Runx2 단백질을 안정화시키고 그와 동시에 Runx2 유전자 전사 및 골
형성 관련 유전자의 발현을 활성화시킴으로써 세포의 증식 및 조골세포
분화를 촉진하여 궁극적으로 CCD의 뼈 이상 회복 효과를 야기하였음을
보였다. 이 연구 결과는 약물치료법이 전무했던 CCD 질환에 대한 치료
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제 개발 가능성을 열었다는 것과 MS-275에 의한 골전구세포 분화기전
을 실험적ㆍ정보학적으로 규명하였다는데 의의가 있다. 
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